doi: 10.1172/jci.insight.165356 202 GirisaSAswaniBSManickasamyMKHegdeMAlqahtaniMSAbbasMet al
Evidence suggests that integrated care pathways lead to improvements, including reduced hospitalizations and enhanced quality of life
However, pharmacokinetic studies suggest that these comorbidities do not affect the pharmacokinetics of oral semaglutide, and based on the observed safety profiles, no dose adjustments are recommended [68, 69]
Given the popularity of and rapid rise in the use of this class of receptor agonists, the need for this guidance has become increasingly urgent
The second strategy focuses on DPP-4 inhibitors, which prevent the rapid degradation of endogenous GLP-1 by inhibiting the DPP-4 enzyme, thereby extending the hormone's activity
If you are using or considering Empower Pharmacy semaglutide, these findings should factor into your decision